Delta-8 THC and Its 11-Hydroxy Metabolite Showed Reciprocal Catalepsy Cross-Tolerance in Mice
A 1983 mouse study found tolerance to delta-8 THC and 11-hydroxy-delta-8 THC, with cross-tolerance in both directions on a catalepsy test. The result concerns a movement-related endpoint after controlled intravenous exposure.
Parent compound and metabolite were tested separately
Mice received daily intravenous administration of either compound. Subsequent dose-response comparisons showed that larger doses were needed for the measured cataleptogenic effect than in vehicle-treated animals. The study directly administered the metabolite rather than inferring its effect from metabolism of the parent.
Reciprocal did not mean numerically identical
Both pretreatment histories shifted responses to both compounds, but the dose estimates differed across pretreatment and challenge combinations. A shared direction of adaptation does not demonstrate identical potency or an exact conversion between the parent and metabolite.
Catalepsy is a specific experimental response
The assay measures a movement-related state, not subjective intoxication or every motor function. The findings do not establish tolerance to memory effects, heart-rate changes or other endpoints. They also do not compare delta-8 products with contemporary delta-9 cannabis use in people.
This study supports overlap in the tested effects of a cannabinoid and its metabolite. It cannot establish that delta-8 is mild, that a tolerant person is unimpaired or that intravenous mouse doses translate into consumer dosing. Compound identity, route and behavioral measure remain essential.
Related: interpreting cannabis tolerance claims.
Research cited
Watanabe K; Yamamoto I; Yoshimura H. Development of tolerance and cross-tolerance to the cataleptogenic effects of delta 8-tetrahydrocannabinol and 11-hydroxy-delta 8-tetrahydrocannabinol in mice. European journal of pharmacology (1983). doi:10.1016/0014-2999(83)90427-2. Findings discussed from the study abstract.
